Article Text

Download PDFPDF
A naturalistic study of the determinants of health related quality of life improvement in osteoarthritic patients treated with non-specific non-steroidal anti-inflammatory drugs
  1. V Rabenda1,
  2. N Burlet1,
  3. O Ethgen1,
  4. F Raeman2,
  5. J Belaiche3,
  6. J-Y Reginster1
  1. 1Department of Epidemiology, Public Health and Health Economics, University of Liège, Liège-Belgium and World Health Organisation (WHO) Collaborating Centre for Public Health Aspects of Rheumatic Diseases, Liège, Belgium
  2. 2Department of Internal Medicine, AZ Jan Palfijn Hospital, Antwerp, Belgium
  3. 3Department of Gastroenterology, CHU Sart-Tilman, University of Liège, Liège, Belgium
  1. Correspondence to:
    Mrs V Rabenda
    Service de Santé Publique, Epidémiologie et Economie de la Santé, 3 avenue de l’Hôpital, Bâtiment 23, CHU Sart-Tilman, 4000 Liège, Belgium; veronique.rabendaulg.ac.be

Abstract

Objectives: To capture changes in the quality of life (QoL) occurring in patients with osteoarthritis (OA) during treatment with non-specific non-steroidal anti-inflammatory drugs (NSAIDs) and to identify factors that predict such changes.

Methods: A naturalistic, prospective follow up of 783 patients with OA in whom primary care physicians decided to start treatment with non-selective NSAIDs. Short Form-36 (SF-36) and the Western Ontario and McMaster Universities OA index (WOMAC) were assessed at baseline and after 3 months. Baseline results were compared with QoL values in 4800 subjects randomly selected from the general population. Multiple regression analysis was performed to identify determinants of QoL at baseline and measures influencing changes in SF-36 or WOMAC during follow up.

Results: All QoL dimensions were significantly (p<0.01) decreased in patients with OA compared with controls. Significant improvement (p<0.05) in four dimensions of the SF-36 (vitality, role emotional, role physical, bodily pain) and in all components of the WOMAC was seen between baseline and month 3. Older age, female sex, longer duration of OA, and a higher number of comorbidities were the major determinants of a poor QoL at baseline. Maximal benefit from non-specific NSAIDs was seen in patients with the most severe impairment in QoL and the shortest duration of OA.

Conclusion: OA negatively impacts all dimensions of the QoL. Non-specific NSAIDs improve the QoL in patients with OA treated in a “real life setting”. The profile of patients receiving maximal benefit from such treatment may be of interest for health providers, enabling them to decide who should preferentially be given cytoprotective treatments or coxibs.

  • coxibs, cyclo-oxygenase-2 inhibitors
  • GI, gastrointestinal
  • GPD, gastroprotective drug
  • GPs, general practitioners
  • NSAIDs, non-steroidal anti-inflammatory drugs
  • OA, osteoarthritis
  • QoL, quality of life
  • RCTs, randomised controlled trials
  • SF-36, Short Form-36
  • WOMAC, Western Ontario and McMaster Universities Osteoarthritis Index
  • non-steroidal anti-inflammatory drugs
  • age
  • osteoarthritis
  • quality of life
  • treatment

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes